Results 161 to 170 of about 22,517 (214)

Long-term octreotide treatment of metastatic carcinoid tumor

, 2000
V.D. Corleto, Stefano Angeletti, Orazio Schillaci, Massimo Marignani, M Caratozzolo, Francesco Panzuto, Bruno Annibale, Gianfranco Delle Fave   +7 more
openalex   +1 more source

The role of octreotide in preventing complications after pancreatoduodenectomy for cancer

, 2000
Åke Andrén‐Sandberg, G Flati, Markus W. Büchler   +2 more
openalex   +1 more source

Prevention of intra-abdominal complications after pancreatic resection by octreotide. A prospective, multicenter, randomized trial

, 2000
P Oberlin, Bertrand Sue, Denis Pezet, Pierre‐Louis Fagniez, Jean‐Marie Hay   +4 more
openalex   +1 more source

Effect of octreotide on portal pressure in patients with TIPS in relation to portal vascular resistance and to octreotide and glucagon levels

, 2000
Burkard Goeke, Tilman Sauerbruch
openalex   +1 more source

Sandostatin LAR (long acting octreotide acetate) for carcinoid syndrome: A one year experience

, 2000
Martyn Caplin, Daniel Hochhauser, A J Hilson, Andrew K. Burroughs, A.F. Watkinson, J. Tibbals, B.R. Davidson, John Buscombe   +7 more
openalex   +1 more source

Sustained reduction of portal pressure by administration of octreotide — LAR in portal hypertensive rats

, 2000
Katerina Kotzampassi, Dimitrios Koufogiannis, E. Eleftheriadis   +2 more
openalex   +1 more source

Octreotide acetate pretreatment in the prevention of post-ERCP abdominal pain

, 2000
Marko Duvnjak, Vladimir Supanc, Velimir Šimičević, Davor Hrabar, Branko Troskot, Tatjana Supanc   +5 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Octreotide and Octreotide-derived delivery systems

Journal of Drug Targeting, 2023
Pharmaceutical peptide Octreotide is a somatostatin analog with targeting and therapeutic abilities. Over the last decades, Octreotide has been developed and approved to treat acromegaly and neuroendocrine tumours, and Octreotide-based radioactive conjugates have been leveraged clinically to detect small neuroendocrine tumour sites.
Mingliang, Fan, Yue, Huang, Xinlin, Zhu, Jiayu, Zheng, Mingwei, Du   +4 more
openaire   +2 more sources

Physical-chemical characterization of octreotide encapsulated in commercial glucose-star PLGA microspheres.

Molecular Pharmaceutics, 2020
Sandostatin LAR is an injectable long-acting release (LAR) microsphere formulation for octreotide based on a biodegradeable glucose star copolymer of D,L-lactic and glycolic acids (PLGA-glu), which is primarily used for the treatment of patients with ...
Avital Beig, Linglin Feng, Jennifer Walker, Rose Ackermann, Justin K. Y. Hong, Tinghui Li, Yan Wang, Bin Qin, S. Schwendeman   +8 more
semanticscholar   +1 more source

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Journal of Clinical Oncology, 2009
PURPOSE Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metastatic NETs is a matter of debate ...
A. Rinke, H. Müller, C. Schade-Brittinger, K. Klose, P. Barth, M. Wied, C. Mayer, B. Aminossadati, U. Pape, M. Bläker, J. Harder, C. Arnold, T. Gress, R. Arnold   +13 more
semanticscholar   +1 more source